Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly

Eli Lilly and Company

LégiaPark is an economic activity center dedicated to hosting companies active in life sciences. It provides a suitable environment for research, production, or commercialization activities.

LégiaPark

CompaniesMarketcap provides market capitalization data and rankings for publicly listed companies

CompaniesMarketcap

Cordia Pharma LTD UK operates in the healthcare industry, providing business process optimization, technology solutions, strategic sourcing, and digital transformation services. This description is self-described.

Metric
Company Name	Eli Lilly and Company	LégiaPark	CompaniesMarketcap	Cordia Pharma LTD UK
Symbol	LLY
MSH ID	COM:LILLY	BE:LEGIAPARK	COM:COMPANIESMARKETCAP	COM:CORDIAPHARMA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Commercial & Professional Services	Financial Services & Finance	Commercial & Professional Services
Industry	Drug Manufacturers - General	Life Sciences	Financial Data & Analytics	Healthcare & Health Services
Country	US	BE	US	GB
Stage
Employee Count	43K
Website	lilly.com	legiapark.be	companiesmarketcap.com/exxon-mobil	cordiapharma.com
LinkedIn		l%C3%A9giapark		cordia-pharma-ltd
Founders

Metric
Market Cap	893.17B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	34.12B
Revenue (LTM)
Revenue (NTM)
Gross Profit	27.55B
EBITDA	12.46B
Operating Income	10.33B
Net Income	5.24B
EPS	5.82
Diluted EPS	5.80
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.81
Operating Profit Margin	0.27
EBITDA Margin	0.37
Net Profit Margin	0.23
Return on Equity	0.61
Return on Assets	0.10
Return on Capital Employed	0.23

COM:LILLY

Eli Lilly and Company

Last Close

749.92

22/11 21:00

Market Cap

893.17B

Beta: -

Volume Today

4.01M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	127.25
P/B Ratio	56.57
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	27.04
EV Multiple	115.09

Metric
Days Sales Outstanding	117.94
Days Payables Outstanding	129.90
Days Inventory Outstanding	327.50
Operating Cycle	452.72
Cash Conversion Cycle	323.73
Asset Turnover	0.56

Metric
Operating Cash Flow	4.24B
Free Cash Flow	-3.15B
Cash Flow to Debt	0.17
Operating Cash Flow/Sales	0.14
Free Cash Flow Yield	-0.00

Metric
Cash & Equivalents	2.82B
Accounts Receivable	-2.45B
Inventory	5.77B
Goodwill	4.94B
Debt to Capitalization	0.70
Debt to Assets	0.35
Current Ratio	1.05
Quick Ratio	1.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.27
SG&A to Revenue	0.22